Headlines about Atossa Genetics (NASDAQ:ATOS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Atossa Genetics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.7708550997485 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

Shares of Atossa Genetics (NASDAQ ATOS) traded up 0.943% on Monday, hitting $0.535. The stock had a trading volume of 699,143 shares. The company has a 50 day moving average price of $0.45 and a 200-day moving average price of $0.62. The stock’s market cap is $6.26 million. Atossa Genetics has a 12 month low of $0.32 and a 12 month high of $2.60.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.20). On average, equities research analysts anticipate that Atossa Genetics will post ($3.57) earnings per share for the current year.

WARNING: “Atossa Genetics (ATOS) Given Daily News Impact Rating of 0.11” was published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/atossa-genetics-atos-given-daily-news-impact-rating-of-0-11/1603686.html.

About Atossa Genetics

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

Insider Buying and Selling by Quarter for Atossa Genetics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.